On June 5, 2025, Knight Therapeutics Inc., a pan-American specialty pharmaceutical company, entered into a series of exclusive license and supply agreements with Sumitomo Pharma America Inc. to commercialize MYFEMBREE®, ORGOVYX®, and vibegron in Canada, and an asset purchase agreement to acquire certain mature pharmaceutical products.
For Knight, the acquisition is a significant step in its ongoing growth strategy, further strengthening its portfolio in women’s health and urology, and expanding access to innovative therapies for Canadian patients and healthcare providers. Moreover, this transaction aligns with Sumitomo’s strategic focus on its core U.S. brands and the acceleration of its pipeline assets in oncology, regenerative medicine and cell therapy.
Davies Ward Phillips & Vineberg LLP represented Knight in this transaction. The team included Hillel Rosen, Shayna Goldman, Amélie Doyon and Mehlka Mustansir (Corporate); Max Jarvie and Gabriel Boulianne Gobeil (Privacy); and Taj Kudhail (Tax).
Gibbons P.C. represented the vendor.